First symptom of onset was Raynaud phenomena 91.3% of the cases, followed by skin changes (56.5%), puffy fingers (52,2%), gastrointestinal and musculoarticular symptoms (23.9% each). The medium duration between the first symptom and a medical consult was 6 (63.5) months. The first medical consult was done by a internal medicine specialist -38.3%, by a rheumatologist-29.8%, a gastroenterologist-12.8%, a dermatologist-8.5%, a nephrologist and a pneumologist-4.2% and neurologist 2.1% The first suspected diagnosis was SSc in 14 cases, Raynaud syndrome in 8, connective tissue disease in 5, rheumatoid arthritis in 4, cancer, autoimmune hepatitis, idiopathic pulmonary fibrosis each in 2 cases and none in 10 cases. The medium number of consults until final diagnosis was 3.4 (1.7). The medium duration from the first symptom until the correct diagnosis was 39.2 (74) months. The first investigations recommended were blood tests in almost all of the patients (95.7%), but only a third of them included specific scleroderma autoantibodies. Capillaroscopy was performed as an initial diagnostic test in only 6 patients (12.8%). The mean interval from disease onset until the patient was referred to the first capillaroscopy was 13.5 (28.8) months, to specific autoantibodies was 40.17 (61.3) month, to echocardiography was 36.38 (54) months, to lung function tests and lung months. There were no significant statistical differences between patients coming from rural environment and those coming from urban environment. The only significant statistical difference between diffuse and limited subset was the time the patient was referred to echocardiography (19.8 (47.6 ) months for the diffuse subset, 66.8 (94.6) months for the limited subset, p=0.04). The only statistical difference between males and females was related to the interval that capillaroscopy was performed (14 (20.5)months in females, 4.8 (5) months in males, p=0.02). Conclusions: Scleroderma is a less well-known disease. This lack of awareness contributes to delayed diagnosis and delayed onset of therapy. Often such diagnostic uncertainty and frustration takes a huge toll on the psychological well-being of these patients, who describe their journey to diagnosis as being one of the most difficult part of their illness. One of our missions as rheumatologist is to increase recognition of this disorder. for at least one autoAb: anti-Topo I abs in 54 (41.2%), anti-CENPA in 37 (28.2%, all reactive with CENPB), anti-RNA polymerase III (RP11) in 19 (14.5%), anti-RNA polymerase III (RP155) in 13 (9.9%), anti-fibrillarin in 4 (3.1%), anti-Ku in 6 (4.6%), anti-NOR90 in 8 (6.1%), anti-PM/Scl100 in 2 (1.5%), and anti-PM/Scl75 in 4 (3.1%). There was no immunoreactivity for Th/To or PDGFR. Overall, 102 (77.9%) SSc patients had autoAbs against Topo I, CENPA or CENPB, RP11 or RP155. Anti-Topo I abs were strongly associated with dcSSc, interstitial lung disease (ILD) (p<0.001), and pulmonary arterial hypertension (PAH) (p=0.019). Anti-CENB abs were associated with lcSSc, and negatively associated with ILD. Anti-RP11 and anti-NOR90 abs were associated with male gender, and anti-NOR90 associated with ILD. In PR individuals and healthy individuals anti-Ro52 immunoreactivity was found in 9.1% and 13.6%, respectively, but no other immunoreactivity was detected.
Conclusions: Anti-Scl70, anti-CENP and anti-RNA pol III are the most prevalent autoAbs in SSc. Anti-Topo I and anti-NOR90 abs are associated with ILD and/or PAH. 
Conclusions:
Our data showed similar results to the local and european cohorts. We found fewer calcinosis and digital tip ulcers in both lSS and dSS than international cohorts. A lower prevalence of PH was reported in lSS respect to other series, and it might be atributed to the method wich it was measured. (right heart catheterism). 
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Background: Anti-topoisomerase antibodies (ATA) in systemic sclerosis (SSc) have been associated with poorer prognosis including diffuse skin involvement, pulmonary fibrosis, cardiac involvement and increased mortality. However, 30-60% of ATA-positive SSc patients demonstrate only limited skin involvement and some have only mild disease course. In SSc, optimal risk stratification is of utmost importance for tailored clinical management at the patient level. Objectives: We aimed to determine the prevalence of mild disease among ATA positive patients and to investigate which readily available clinical parameters best identify patients with highest disease severity. Methods: Clinical baseline data from SSc patients included in the Combined Care In Systemic Sclerosis (CCIS) cohort of the Leiden University Medical Center were extracted. Patients fulfilling ACR 2013 criteria and ATA positive were included. Descriptive statistics were used to summarize sociodemographic, clinical and serological features. Patients with grade 3 or 4 disease on any of the Medsger severity subscales were considered to be severely diseased. We compared presence of diffuse cutaneous involvement, Raynaud's, pitting scars, calcinosis, proximal muscle weakness, >10% weight loss, interstitial lung disease and pro-BNP between the severity groups and corrected for confounding by disease duration (time since non-Raynaud) by stratifying into quartiles.
Results:
Of 422 SSc patients in the database, 344 patients had SSc meeting ACR criteria. 89 patients were exclusively ATA-positive, of which n=42 with mild disease and n=47 with severe disease. Patients with severe disease appeared to be younger (mean age 50 vs 55 yr), more often non-caucasian (51 vs 12%), with a longer time since non-Raynaud (median 4 vs 2 yr) and more often diffuse skin involvement (dcSSc;62 vs 41%), calcinosis (6 vs 0%) and weight loss (23 vs 7%). Stratification by disease duration, however revealed there are no real differences between mild en severe disease. Overall 47% of ATA+ patients in our cohort presented with mild SSc. When stratifying patients according to time of non-Raynaud, 55% of ATA+ patients presented with mild disease in the first disease duration quartile (median follow-up 0.5 years, range 0-0.8 years). In the forth disease duration quartile, according non-Raynaud time (median follow-up 12.7 years, range 8.2-44.1) the percentage with mild disease was still 27% (Figure 1 ). Background: The pathogenesis of interstitial lung disease associated with systemic sclerosis (SSc-ILD) is not completely elucidated, although it is believed that chronic alveolar inflammation leads to increasing fibrosis. Treatment strategies using cyclophosphamide (CYC) have been focusing on the inflammatory pathway of SSc-ILD. We hypothesized that CYC is more effective in patients that are in the early, inflammatory phase. Objectives: The objectives of this study are to analyze the effects of intravenously CYC pulses (750mg/m 2 ) on pulmonary function (FVC, DLCO) in SSc-ILD after 12, 24 and 36 months, and whether this effect is dependent on the extent of ILD, the proportion of ground glass compared to fibrosis, SSc disease duration or baseline DLCO <60%. Methods: Patients with SSc-ILD receiving CYC pulses between 2003 and 2015 were classified by the Goh (2008) criteria in either limited or extensive ILD, using HRCT at baseline independently judged by two raters. Pulmonary function tests were performed at 0, 6, 12, 24 and 36 months. Missing outcome data due to drop-out were replaced by last observation carried forward, except in case of death. Results: Seventy-five patients were included, 33 with limited ILD, 42 with extensive ILD. There were no baseline differences in age, gender, SSc subtype classification, disease duration or autoantibody status. Mean FVC and DLCO were stable after 12, 24 and 36 months of follow-up (figure 1). There was no effect in the degree of change in mean FVC and DLCO for the different effect modifiers (table 2): the extent of ILD, proportion of ground glass compared to fibrosis, short SSc disease duration or baseline DLCO <60%. Conclusions: Mean FVC and DLCO in SSc-related ILD was stable during 36 months of follow-up after cyclophosphamide pulse therapy. The extent of ILD, proportion of ground glass, SSc disease duration and baseline DLCO <60% did not influence the effect of CYC on pulmonary function. CYC did not appeare to be more effective in the early phase of SSc-ILD. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.3441 
Conclusions
